{"entity":{"id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial testing AL8326 in small-cell lung cancer and non-small-cell lung cancer, now recruiting.","summary":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06247605, led by Advenchen Laboratories Nanjing, and recruiting on the registry. Official title: Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment. Planned enrolment is 243 participants (estimated). The study started in 2023-10-26 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06247605","url":"https://clinicaltrials.gov/study/NCT06247605"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["al8326"],"companies":["advenchen-laboratories"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06247605","phase":"3","setting":"Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment","sponsor":"Advenchen Laboratories Nanjing","started":"2023-10-26","startedType":"actual","enrolled":243,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06247605/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/"}],"company":[{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/"}]}}